Cite
HARVARD Citation
Cardoso, F. et al. (n.d.). 24TiPKEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer. Annals of oncology. p. . [Online].